Adam Smith Business School
Glasgow, Scotland G12 8LE
United Kingdom
SGLT2 inhibitors; GLP-1 receptor agonists; bariatric surgery; all-cause mortality; cardiovascular diseases; end-stage renal diseases; severe hypoglycaemia; obesity; type 2 diabetes mellitus